Divyaswathi Citla Sridhar and Team Report Higher VTE Rates in Obese Users of Certain Estrogen-Progestin Combinations
RPTH Journal shared on LinkedIn:
”Does obesity amplify clot risk with hormonal therapy?
A massive database study from Divyaswathi Citla Sridhar, MD MS and team reports higher VTE rates in obese users of certain estrogen-progestin combinations—but not with progesterone-only therapy.
Curious which regimens carry the greatest risk?
Co-authors: Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel Rosovsky, and Nancy Sokkary”
Read the full article in RPTH.
Article: Venous thromboembolism in obese hormonal contraceptive users: a large national database study
Authors: Divyaswathi Citla-Sridhar, Madhvi Rajpurkar, Lakshmi Srivaths, Bethany Samuelson Bannow, Rachel P. Rosovsky, Nancy Sokkary
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 1, 2026, 05:44Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?